Transdermal nitroglycerine as a coadjuvant to intrathecal nalbuphine with bupivacaine in lower abdominal surgery

Abstract

Background The purpose of this study was to evaluate the effect of transdermal nitroglycerine patch as a coadjuvant to intrathecal nalbuphine with bupivacaine in patients undergoing lower abdominal surgery. Patients and methods A total of 120 patients (ASA I or II) were randomized into two equal groups in this double-blind, placebo-controlled trial. The control group (group C) received intrathecal 0.5% hyperbaric bupivacaine 15 mg (3 ml) plus 0.8 mg (0.4 ml) preservative-free nalbuphine plus transdermal placebo patch, and the study group (group NG) received intrathecal 0.5% hyperbaric bupivacaine 15 mg (3 ml) plus 0.8 mg (0.4 ml) preservative-free nalbuphine plus transdermal nitroglycerine patch (5 mg). The transdermal patch (either nitroglycerine or placebo) was applied on the chest 20 min after spinal injection. Pain intensity, hemodynamics, and adverse effects were evaluated. Results Patients in group NG had longer duration of effective analgesia with subsequent longer time for the first rescue analgesic (482.6 ± 16.3 min) compared with group C (334.2 ± 15.6 min) ( P P P > 0.05). Conclusion Transdermal nitroglycerine (5 mg) significantly prolonged the analgesic effect of intrathecal nalbuphine and provided effective postoperative analgesia after lower abdominal surgery.